EQT Life Sciences, the life sciences investment arm of Swedish private equity group EQT, has invested in Boston-based developer of respiratory drugs Kinaset Therapeutics as part of a $103 million Series B funding round. The funding will support the development of frevecitinib, a new inhaled treatment for asthma patients whose condition is not well controlled by existing therapies.



